MentalHealthDaily

Deep Brain Stimulation (DBS) of Nucleus Accumbens (NAc) for Treatment-Resistant Depression (4 Case Reports)

Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD) explores the cutting-edge intersection of technology and neuroscience, offering hope to those for whom traditional treatments have failed. By targeting specific brain areas, such as the nucleus accumbens, DBS attempts to modulate the underlying neural circuits associated with depression. A recent review analyzed case reports documenting significant …

Tramadol for Depression: Highly Effective as Off-Label Antidepressant (According to User Reviews)

by GLOOM

Tramadol, commonly known for its pain-relieving properties, has emerged as an effective off-label treatment for depression according to patient experiences and reviews. A recent analysis of tramadol’s antidepressant potential examined user feedback – comparing its efficacy and safety with established antidepressants. It considered the perspectives of patients who have found relief from depression with tramadol, …

Are Mystical Experiences Required for the Antidepressant Effects of Ketamine & Psychedelics?

by GLOOM

The intersection of mental health treatment and pharmacology is witnessing a remarkable shift with the growing interest in ketamine and classic psychedelics like psilocybin for their rapid and sustained antidepressant effects. Unlike traditional antidepressants, these substances offer hope for those with treatment-resistant depression by potentially transforming treatment paradigms. However, it remains somewhat unclear as to …

Tianeptine Trends in the U.S.: Antidepressant, Nootropic, Street Drug (“Gas Station Heroin” & ZaZa)

by GLOOM

Tianeptine is an atypical antidepressant that has been approved in several countries for treating depression but is not authorized for medical use in the United States. Despite this, it has found a significant market in the U.S. as a nootropic, often sold under names like ZaZa or Tianna Red, and has been nicknamed “gas station …

Ketamine Increases Amygdala Volume in Treatment-Resistant Depression (TRD) (2024 MRI Study)

by GLOOM

Depression is a complex mental health condition that significantly affects an individual’s emotional and physical well-being. Recent advances in neuroimaging have provided deeper insights into how major depressive disorder (MDD) alters brain structures, particularly the hippocampus and amygdala, and how treatments like ketamine can potentially reverse these changes. A new study using 3T and 7T …

Nortriptyline-Induced “Room Tilt Illusion”: A Rare Adverse Event of Antidepressants (2024 Case Report)

by GLOOM

Room Tilt Illusion (RTI) presents a perplexing challenge to both patients and physicians, transforming the familiar into the surreal as surroundings appear rotated or flipped. This rare condition, often linked to neurological or vestibular disorders, has recently been observed as an adverse effect of the antidepressant nortriptyline, used in treatment-resistant depression. A case report highlights …

Empagliflozin for Depression: Effective Adjunct with SSRIs (2024 Clinical Trial)

by GLOOM

Major Depressive Disorder (MDD) impacts millions globally, making it a significant public health challenge. Traditional treatments like Selective Serotonin Reuptake Inhibitors (SSRIs) don’t work for everyone, highlighting the need for innovative approaches. Recent clinical trials exploring the use of empagliflozin, a medication originally used to lower blood sugar in diabetes patients, have shown promising results …